Compare Royal Bank of Canada (RY) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Bank of Canada vs TransMedics Group Inc — how do they compare? Royal Bank of Canada trades at $212.57 (market cap $292.32B), while TransMedics Group Inc trades at $87.34 (market cap $3.10B). The key difference: Royal Bank of Canada is far larger — about 94.3× TransMedics Group Inc's market cap, and Royal Bank of Canada pays a 2.37% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| RY | TMDX | |
|---|---|---|
Market Cap | $292.32B | $3.10B |
Sector | Financials | Technology |
52-Week High | $217.87 | $150.42 |
52-Week Low | $134.80 | $61.99 |
Dividend Yield | 2.37% | — |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Bank of Canada (RY) trades at $210.79, down slightly by 0.14% today. The stock shows a bullish technical trend with strong earnings performance, beating EPS estimates in three consecutive quarters. Revenue grew to $66.53 billion in 2025, with a net income margin of 31.85%. Analyst sentiment is mixed with a Buy consensus of 43% but a majority Hold rating. Recent insider selling and a dividend announcement highlight corporate activity.
RY presents a stable investment with solid profitability and dividend yield, but faces risks from high valuation multiples and macroeconomic sensitivity. Upside is supported by earnings growth and institutional holdings, while insider sales and debt levels warrant caution. The stock remains a core holding for dividend-focused portfolios amid moderate growth expectations.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
